CGON (CG Oncology) EV-to-Revenue : 1,893.20 (As of May. 27, 2025)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CG Oncology's enterprise value is $1,253.30 Mil. CG Oncology's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.66 Mil. Therefore, CG Oncology's EV-to-Revenue for today is 1,893.20.

The historical rank and industry rank for CG Oncology's EV-to-Revenue or its related term are showing as below:

CGON' s EV-to-Revenue Range Over the Past 10 Years
Min: 916.57 Med: 2363.43 Max: 15506.95
Current: 1893.2

During the past 4 years, the highest EV-to-Revenue of CG Oncology was 15506.95. The lowest was 916.57. And the median was 2363.43.

CGON's EV-to-Revenue is ranked worse than
96.39% of 997 companies
in the Biotechnology industry
Industry Median: 7.28 vs CGON: 1893.20

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-27), CG Oncology's stock price is $25.00. CG Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.01. Therefore, CG Oncology's PS Ratio for today is 2,272.73.

CG Oncology EV-to-Revenue Historical Data

The historical data trend for CG Oncology's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology EV-to-Revenue Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

1,266.34

CG Oncology Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-Revenue	Get a 7-Day Free Trial						4,377.02	2,387.59	2,935.37	1,266.34	1,781.35

Competitive Comparison of CG Oncology's EV-to-Revenue

For the Biotechnology subindustry, CG Oncology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where CG Oncology's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

CG Oncology EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

CG Oncology's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	1253.299	/	0.662
	=	1,893.20

CG Oncology's current Enterprise Value is $1,253.30 Mil.
CG Oncology's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.66 Mil.

CG Oncology (NAS:CGON) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

CG Oncology's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	25.00	/	0.011
	=	2,272.73

CG Oncology's share price for today is $25.00.
CG Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

CG Oncology EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of CG Oncology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.